Continuous glucose monitoring: Current clinical use

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue SUPPL.2, 2012, Pages 73-78

  Kim, Hun Sung ^a   Shin, Jeong Ah ^a   Chang, Jin Sun ^a   Cho, Jae Hyoung ^a   Son, Ho Young ^a   Yoon, Kun Ho ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Closed loop system; Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Diabetes mellitus; Insulin pump

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

BLOOD GLUCOSE MONITORING; CLINICAL PRACTICE; CONTINUOUS GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; EVIDENCE BASED PRACTICE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFORMATION TECHNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MEDICAL EDUCATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION;

BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MONITORING, AMBULATORY;

EID: 84871827817     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2346     Document Type: Review

References (35)

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
3. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the ADA and the EASD. Diabetes Care 2006;29:1963-72.
4. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the ADA and the EASD. Diabetologia 2006;49:1711-21.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
6. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-81.
7. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
8. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-40.
9. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 2002;25:829-34.
10. Kim JS, Kim YJ, Park SI, Hong YP. Mean fasting blood glucose level and an estimated prevalence of diabetes mellitus among a representative adult Korea population. Korean J Prev Med 1993;26:311-20.
11. Mastrotorato J. The MiniMed continuous glucose monitoring system (CGMS). J Pediatr Endocrinol Metab 1999;12:751-8.
12. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-76.
13. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2011;32:S11-61.
14. Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009;32:2245-50.
15. O'Connell MA, Donath S, O'Neal DN, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009;52:1250-7.
16. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-20.
17. Lelio M, Alessandra DF, Angelo L, et al. Continuous subcutaneous insulin infusion (CSII) in inpatient setting: unmet needs and the proposal of a CSII unit. Diabetes Technol Ther 2011;13(10): 1071-4.
18. Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-totarget study. Diabetes Technol Ther 2008;10:377-83.
19. Hermanides J, Nørgaard K, Bruttomesso D, et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled type 1 diabetes: a randomized controlled trial. Diabet Med 2011;28:1158-1167.
20. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010;375:743-51.
21. Murphy HR, Elleri D, Allen JM, et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 2011;34:406-11.
22. Chitayat L, Zisser H, Jovanovic L. Continuous glucose monitoring during pregnancy. Diabetes Technol Ther 2009;11(Suppl 1): S105-11.
23. Kestila KK, Ekblad UU, Ronnemaa T. Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus. Diabetes Res Clin Pract 2007;77:174-9.
24. McLachlan K, Jenkins A, O'Neal D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Aust N Z J Obstet Gynaecol 2007;47:186-90.
25. Yogev Y, Ben-Haroush A, Chen R, Kaplan B, Phillip M, Hod M. Continuous glucose monitoring for treatment adjustment in diabetic pregnancies-a pilot study. Diabet Med 2003;20:558-62.
26. Goldberg PA, Siegel MD, Russell RR, et al. Experience with the continuous glucose monitoring system in a medical intensive care unit. Diabetes Technol Ther 2004;6:339-47.
27. Buckingham B, Cobry E, Clinton P, et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009;11:93-7.
28. The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1468-78.
29. McQueen RB, Ellis SL, Campbell JD, Nair KV, Patrick W, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc 2011:9(13): 1-8.
30. Amanda B, Perry B. The role of reimbursement in the adoption of continuous glucose monitors. J Diabetes Sci Technol 2009;3(4): 992-5.
31. Ginsberg BH. The FDA Panel advises approval of the first continuous glucose sensor. Diabetes Technol Ther 1999;2:203-4.
32. Baek YH, Jin HY, Lee KA, et al. The correlation and accuracy of glucose levels between interstitial fluid and venous plasma by continuous glucose monitoring system. Korean Diabetes J 2010;34:350-8.
33. Wentholt IM, Vollebregt MA, Hart AA, Hoekstra JB, DeVries JH. Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 2005;28:2871-6.
34. Cho JH, Kim HS, Han JH, et al. Ubiquitous diabetes management system via interactive communication based on information technologies: clinical effects and perspectives. Korean Diabetes J 2010;34:267-74.
35. Cho JH, Choi YH, Kim HS, Lee JH, Yoon KH. Effectiveness and safety of a glucose data-filtering system with automatic response software to reduce the physician workload in managing type 2 diabetes. J Telemed Telecare 2011;17:257-62.